Logo AZARGA® eye drops, suspension


(and dosage form)

AZARGA® eye drops, suspension

1 mL of suspension contains 10 mg
brinzolamide and 5 mg timolol (as timolol maleate).
Preservative: benzalkonium chloride 0.01% (w/v).
Preservative aid: disodium edetate 0.01% (w/v).

A 15.4 Ophthalmic preparations, other
ATC code: S01ED51

Pharmacodynamic properties
Mechanism of action
AZARGA® contains two active substances: brinzolamide and timolol maleate. These two components decrease elevated Intra-ocular Pressure primarily by reducing aqueous humour secretion, but do so by different mechanisms of action. The combined effect of these two agents results in additional Intra-ocular Pressure reduction compared to either compound alone.
Brinzolamide is a potent inhibitor of human carbonic anhydrase II (CA-II), the predominant iso-enzyme in the eye. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Timolol is a non-selective beta-adrenergic blocking agent that has no intrinsic sympathomimetic, direct myocardial depressant or membrane-stabilising activity. Tonography and fluorophotometry studies in man suggest that its predominant action is related to reduced aqueous humour formation and a slight increase in outflow facility.
Pharmacokinetic properties
Following topical ocular administration, brinzolamide and timolol are absorbed through the cornea and into the systemic circulation. In a pharmacokinetic study, healthy subjects received oral brinzolamide (1 mg) twice daily for 2 weeks to shorten the time to reach steady-state prior to the start of AZARGA® administration. Following twice daily dosing of AZARGA® in both eyes for 13 weeks, red blood cell (RBC) concentrations of brinzolamide averaged 18,8 +3,29 µM, 18,1 +2,68 µM and 18,4 +3,01 µM at weeks 4, 10 and 15, respectively, indicating that steady-state RBC concentrations of brinzolamide were maintained.
At steady state, following administration of AZARGA®, the mean plasma Cmax and AUC0-12h of timolol were 27% and 28% lower (Cmax: 0,824 +0,453 ng/mL; AUC0-12h: 4,71 +4,29 ng h/mL), respectively, in comparison to the administration of timolol 5 mg/mL (Cmax: 1,13 +0,494 ng/mL; AUC0-12h: 6,58 +3,18 ng h/mL). The lower systemic exposure to timolol following AZARGA® administration is not clinically relevant. Following administration of AZARGA®, mean Cmax of timolol was reached at 0,79 +0,45 hours.
Plasma protein binding of brinzolamide is moderate (about 60%). Brinzolamide is sequestered in RBCs due to its high affinity binding to CA-II and to a lesser extent to CA-I. Its active N-desethyl metabolite also accumulates in RBCs where it binds primarily to CA-I. The affinity of brinzolamide and metabolite to RBC and tissue CA results in low plasma concentrations.
Ocular tissue distribution data in rabbits showed that timolol can be measured in aqueous humour up to 48 hours after administration of AZARGA®. At steady state, timolol is detected in human plasma for up to 12 hours after administration of AZARGA®.
The metabolic pathways for the metabolism of brinzolamide involve N-dealkylations, O-dealkylations and oxidation of its N-propyl side chain. N-desethyl brinzolamide is a major metabolite of brinzolamide formed in humans, which also binds to CA-I in the presence of brinzolamide and accumulates in RBCs. In vitro studies show that the metabolism of brinzolamide mainly involves CYP3A4 as well as at least four other isozymes (CYP2A6, CYP2B6, CYP2C8 and CYP2C9).
Timolol is metabolised by two pathways. One route yields an ethanolamine side chain on the thiadiazole ring and the other giving an ethanolic side chain on the morpholine nitrogen and a second similar side chain with a carbonyl group adjacent to the nitrogen. Timolol metabolism is mediated primarily by CYP2D6.
Brinzolamide is eliminated primarily by renal excretion (approximately 60%). About 20% of the dose has been accounted for in urine as metabolite. Brinzolamide and N-desethyl-brinzolamide are the predominant components found in the urine along with trace levels (<1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Timolol and its metabolites are primarily excreted by the kidneys. Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites. The plasma t½ of timolol is 4,8 hours after administration of AZARGA®.

Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

Hypersensitivity to brinzolamide, timolol, or to any of the excipients.
Bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
Severe allergic rhinitis and bronchial hyperreactivity; hypersensitivity to other beta-blockers.
Hyperchloraemic acidosis (see DOSAGE AND DIRECTIONS FOR USE).
Severe renal impairment.
Hypersensitivity to sulphonamides (see WARNINGS).

Special warnings and special precautions for use
Systemic effects
Like other topically applied ophthalmic agents, brinzolamide and timolol are absorbed systemically. Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-adrenergic blocking agents may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be observed for signs of cardiac failure and have their pulse rates checked. Respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported following administration of timolol maleate. Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile insulin-dependent diabetes, as beta-adrenergic blocking agents may mask the signs and symptoms of acute hypoglycaemia. They may also mask the signs of hyperthyroidism and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension.
AZARGA® contains brinzolamide, a sulphonamide. The same types of undesirable effects that are attributable to sulphonamides may occur with topical administration. Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. If signs of serious reactions or hypersensitivity occur, discontinue the use of this medicine.
There is potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and AZARGA®. The concomitant administration of AZARGA® and oral carbonic anhydrase inhibitors has not been studied and is not recommended.
Anaphylactic reactions
While taking beta-adrenergic blocking agents, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.
Concomitant therapy
Timolol may interact with other medicines (see INTERACTIONS).
The effect on intraocular pressure or the known effects of systemic beta-blockade may be potentiated when AZARGA® is given to patients already receiving an oral beta-adrenergic blocking agent. The use of two local beta-adrenergic blocking agents or two local carbonic anhydrase inhibitors is not recommended.
Ocular effects
There is limited experience with AZARGA® in the treatment of patients with pseudoexfoliative glaucoma or pigmentary glaucoma. Caution should be utilised in treating these patients and close monitoring of IOP is recommended.
AZARGA® has not been studied in patients with narrow-angle glaucoma and its use is not recommended in these patients.
Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination in elderly patients. AZARGA® is absorbed systemically and therefore this may occur with topical administration.
The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count). Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for damage to the cornea. Careful monitoring of patients with compromised corneas, such as patients with diabetes mellitus or corneal dystrophies, is recommended.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since AZARGA® contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.
Benzalkonium chloride may cause eye irritation and is known to discolour soft contact lenses. Contact with soft contact lenses is to be avoided. Patients must be instructed to remove contact lenses prior to the application of AZARGA® and wait 15 minutes after instillation of the dose before reinsertion.

No interaction studies have been performed.
AZARGA® contains brinzolamide, a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically. Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. The potential for interactions must be considered in patients receiving AZARGA®.
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main), CYP2A6, CYP2B6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as ketoconazole, itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of brinzolamide by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly. However, accumulation of brinzolamide is unlikely as renal elimination is the major route. Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine or beta-adrenergic blocking agents, antidysrhythmics, digitalis glycosides or parasympathomimetics.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-adrenergic blocking agents.
Potentiated systemic beta-blockade (e.g. decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, cimetidine) and timolol.
Timolol may increase the hypoglycaemic effect of antidiabetic agents. Timolol can mask the signs and symptoms of hypoglycaemia (see WARNINGS).

Safety and efficacy have not been established.
There are no adequate data from the use of brinzolamide in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.
Well-controlled epidemiological studies with systemic use of beta- adrenergic blocking agents did not indicate malformative effects, but some pharmacological effects such as bradycardia have been observed in foetuses or neonates. Data on a limited number of exposed pregnancies indicate no adverse effects of timolol in eye drops on pregnancy or on the health of the foetus/newborn child but bradycardia and arrhythmia have been reported in one case in the foetus of a woman treated with timolol eye drops. To date, no other relevant epidemiological data are available.
AZARGA® should not be used during pregnancy.
It is not known whether brinzolamide is excreted in human breast milk. Animal studies have shown excretion of brinzolamide in breast milk. Timolol does appear in human breast milk. Breastfeeding mothers should not be treated with AZARGA®.

For ocular use.
Use in adults, including the elderly
The dose is one drop of AZARGA® in the conjunctival sac of the affected eye(s) twice daily.
Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.
If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) twice daily.
When substituting another ophthalmic antiglaucoma agent with AZARGA®, the other agent should be discontinued and AZARGA® should be started the following day.
Paediatric patients
AZARGA® is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Use in hepatic and renal impairment
No studies have been conducted with AZARGA® or with timolol 5 mg/mL eye drops in patients with hepatic or renal impairment. No dosage adjustment is necessary in patients with hepatic impairment or in patients with mild to moderate renal impairment.
Brinzolamide has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min) or in patients with hyperchloraemic acidosis. Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZARGA® is therefore contraindicated in patients with severe renal impairment.
Instruct patients to shake the bottle well before use. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Instruct patients to keep the bottle tightly closed when not in use.

Undesirable effects
Summary of the safety profile.
In two clinical trials of 6 and 12 months duration involving 394 patients treated with AZARGA®, the most frequently reported adverse reaction was transient blurred vision (3.6%) upon instillation, lasting from a few seconds to a few minutes.
Tabulated summary of adverse reactions:
The following adverse reactions are classified according to the following convention: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1 000 to <1/100), rare (>1/10 000 to <1/1 000), or very rare (<1/10 000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System Organ Classification MedDRA Preferred
Psychiatric disorders Uncommon: insomnia.
Nervous system disorders Common: dysgeusia.
Eye disorders Common: blurred vision, eye irritation, eye pain, foreign body sensation in eyes
Uncommon: corneal erosion, punctate keratitis, dry eye, eye discharge, eye pruritus, ocular hyperaemia, blepharitis, allergic conjunctivitis, corneal disorder, anterior chamber flare, conjunctival hyperaemia, eyelid margin crusting, astenopia, abnormal sensation in eye, eyelids pruritis, allergic blepharitis, erythema of eyelid.
Vascular disorders Uncommon: decreased blood pressure.
Respiratory, thoracic and mediastinal disorders Uncommon: chronic obstructive pulmonary disease, pharyngolaryngeal pain, cough, rhinorrhoea.
Skin and subcutaneous tissue disorders Uncommon: hair disorder, lichen planus.
Description of selected adverse reactions:
Dysgeusia (bitter or unusual taste in the mouth following instillation) was a frequently reported systemic undesirable effect associated with the use of AZARGA® during clinical studies. It is likely caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal and is attributable to brinzolamide. Nasolacrimal occlusion or gently closing the eyelid after instillation may help reduce the incidence of this effect.
AZARGA® contains brinzolamide which is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption. Gastrointestinal, nervous system, haematological, renal and metabolic effects are generally associated with systemic carbonic anhydrase inhibitors. The same type of undesirable effects that are attributable to oral carbonic anhydrase inhibitors may occur with topical administration.

AZARGA® contains brinzolamide and timolol (as timolol maleate). Additional adverse reactions associated with the use of the individual components observed in clinical trials and postmarketing experience that may potentially occur with AZARGA® include:

Brinzolamide 10 mg/mL Timolol 5mg/mL
Infections and infestations nasopharyngitis, pharyngitis, sinusitis, rhinitis
Blood and lymphatic system disorders red blood cell count decreased, blood chloride increased
Immune system disorders hypersensitivity
Metabolism and nutrition disorders hypoglycaemia
Psychiatric disorders apathy, depression, depressed mood, libido decreased, nightmare, nervousness depression
Nervous system disorders somnolence, motor dysfunction, amnesia, memory impairment, dizziness, paraesthesia, tremor, headache, hypoaesthesia, ageusia cerebral ischaemia, cerebrovascular accident, syncope, myasthenia gravis, paraesthesia, headache, dizziness
Eye disorders keratitis, keratopathy, increased optic nerve cup/disc ratio, corneal epithelium defect, corneal epithelium disorder, increased intraocular pressure, eye deposit, corneal staining, corneal oedema, conjunctivitis, meibomianitis, diplopia, glare, photophobia, photopsia, reduced visual acuity, pterygium, ocular discomfort, keratoconjunctivitis sicca, hypoaesthesia of the eye, scleral pigmentation, subconjunctival cyst, increased lacrimation, visual disturbance, eye swelling, eye allergy, madarosis, eyelid disorder, eyelid oedema diplopia, eyelid ptosis, conjunctivitis, keratitis, visual disturbance
Ear and labyrinth disorders tinnitus, vertigo
Cardiac disorders cardio-respiratory distress, angina pectoris, bradycardia, irregular heart rate, dysrhythmia, palpitations, tachycardia, increased heart rate cardiac arrest, cardiac failure, dysrhythmia, atrioventricular block, bradycardia, palpitations
Vascular disorders Increased blood pressure, hypertension hypotension
Respiratory, thoracic and mediastinal disorders dyspnoea, asthma, bronchial hyperactivity, epistaxis, throat irritation, nasal congestion, upper respiratory tract congestion, postnasal drip, sneezing, nasal dryness respiratory failure, bronchospasm, dyspnoea, nasal congestion
Gastrointestinal disorders dry mouth, oesophagitis, vomiting, diarrhoea, nausea, dyspepsia, upper abdominal pain, abdominal discomfort, stomach discomfort, frequent bowel movements, gastrointestinal disorder, oral hypoaesthesia, oral paraesthesia, flatulence diarrhoea, nausea
Hepatobiliary disorders abnormal liver function test
Skin and subcutaneous tissue disorders urticaria, maculo-papular rash, rash, generalised pruritus, alopecia, skin tightness, dermatitis, erythema alopecia, rash
Musculoskeletal and connective tissue disorders back pain, muscle spasms, myalgia, arthralgia, pain in extremity
Renal and urinary disorders renal pain, pollakiuria
Reproductive system and breast disorders erectile dysfunction
General disorders and administrative site conditions pain, asthenia, chest discomfort, fatigue, feeling abnormal, feeling jittery, irritability, chest pain, peripheral oedema, malaise, medication residue asthenia, chest pain
Injury, poisoning and procedural complications foreign body in eye

Paediatric population
AZARGA® is not recommended for use in children below 18 years due to lack of data on safety and efficacy.

Effects on ability to drive and use machines
As with any eye drops, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.
Oral carbonic anhydrase inhibitors may impair the ability of elderly patients to perform tasks requiring mental alertness and/or physical coordination.

No case of overdose has been reported.
If overdose with AZARGA® eye drops occurs, treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possibly central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that timolol does not dialyse readily.

White to off-white uniform suspension.

Round opaque low density polyethylene bottles with a dispensing plug and white polypropylene screw cap containing 5 mL suspension, packaged inside an outer carton.

Keep out of reach and sight of children.
Discard 4 weeks after opening.
Store in a cool, dry place at or below 30°C.


Alcon Laboratories (SA) (Pty) Ltd
65 Peter Place
Bryanston Ext 13

07 September 2011

New addition to this site: September 2014
Source: Pharmaceutical Industry

Information presented by Malahyde Information Systems © Copyright 1996-2014